Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C P Cross

Showing results (161-170 of 221) with videos related to

Pageof 23
Sort By:
Blood|September 17, 2011
EZH2 mutational status predicts poor survival in myelofibrosisPaola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood|April 24, 2009
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasmsFrancis H Grand, Claire E Hidalgo-Curtis, Thomas Ernst, et al.
Blood|August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsSusan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Annals of Hematology|November 28, 2013
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosisPhilipp Erben, Juliana Schwaab, Georgia Metzgeroth, et al.
Plos One|February 14, 2012
TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemiaCristina Pérez, Nicolas Martínez-Calle, José Ignacio Martín-Subero, et al.
Leukemia|May 23, 2024
Recommendations from the AML molecular MRD expert advisory boardStuart Scott, Alison Devonshire, Richard Dillon, et al.
Genes, Chromosomes & Cancer|January 18, 2018
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosisNicole Naumann, Mohamad Jawhar, Juliana Schwaab, et al.
British Journal of Haematology|January 28, 2009
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clonesPhilip A Beer, Amy V Jones, Anthony J Bench, et al.
Journal of Cancer Research and Clinical Oncology|April 4, 2019
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)Susanne Möbius, Thomas Schenk, Danny Himsel, et al.
Nature Genetics|July 6, 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disordersThomas Ernst, Andrew J Chase, Joannah Score, et al.
Pageof 23

Showing results (161-170 of 221) with videos related to

Sort By:
Pageof 23
Blood|September 17, 2011
EZH2 mutational status predicts poor survival in myelofibrosisPaola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood|April 24, 2009
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasmsFrancis H Grand, Claire E Hidalgo-Curtis, Thomas Ernst, et al.
Blood|August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsSusan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Annals of Hematology|November 28, 2013
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosisPhilipp Erben, Juliana Schwaab, Georgia Metzgeroth, et al.
Plos One|February 14, 2012
TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemiaCristina Pérez, Nicolas Martínez-Calle, José Ignacio Martín-Subero, et al.
Leukemia|May 23, 2024
Recommendations from the AML molecular MRD expert advisory boardStuart Scott, Alison Devonshire, Richard Dillon, et al.
Genes, Chromosomes & Cancer|January 18, 2018
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosisNicole Naumann, Mohamad Jawhar, Juliana Schwaab, et al.
British Journal of Haematology|January 28, 2009
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clonesPhilip A Beer, Amy V Jones, Anthony J Bench, et al.
Journal of Cancer Research and Clinical Oncology|April 4, 2019
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)Susanne Möbius, Thomas Schenk, Danny Himsel, et al.
Nature Genetics|July 6, 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disordersThomas Ernst, Andrew J Chase, Joannah Score, et al.
Pageof 23